Cargando…
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
Lung cancer is the most common cause of cancer death globally with a significant, unmet need for more efficacious treatments. The receptor tyrosine kinase MET has been implicated as an oncogene in numerous cancer subtypes, including non-small cell lung cancer (NSCLC). Here we explore the therapeutic...
Autores principales: | Henry, Ryan E., Barry, Evan R., Castriotta, Lillian, Ladd, Brendon, Markovets, Aleksandra, Beran, Garry, Ren, Yongxin, Zhou, Feng, Adam, Ammar, Zinda, Michael, Reimer, Corinne, Qing, Weiguo, Su, Weiguo, Clark, Edwin, D'Cruz, Celina M., Schuller, Alwin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295379/ https://www.ncbi.nlm.nih.gov/pubmed/27472392 http://dx.doi.org/10.18632/oncotarget.10859 |
Ejemplares similares
-
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
por: Bihani, Teeru, et al.
Publicado: (2014) -
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020) -
Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
por: Han, Sen, et al.
Publicado: (2019) -
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023) -
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)